In­dia of­fers in­cen­tives to do­mes­tic drug­mak­ers for APIs; Af­ter PhI­II tri­als, Tai­ho li­cens­es Arokaris in Japan

In­dia has been de­pen­dent on the im­port of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents to man­u­fac­ture its drugs. But thanks to a a re­cent gov­ern­ment ini­tia­tive, 35 of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.